The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET‐2‐adapted HD0607 trial

The neutrophil to lymphocyte ratio (NLR) and the lymphocyte to monocyte ratio (LMR) can reflect both the myeloid dysfunction and T‐cell immune suppression and have prognostic significance.

[1]  A. Levis,et al.  The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments , 2019, Annals of Hematology.

[2]  D. Aldinucci,et al.  Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It , 2019, International journal of molecular sciences.

[3]  R. Bouabdallah,et al.  PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. , 2019, The Lancet. Oncology.

[4]  A. Ng,et al.  Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. , 2018, Blood advances.

[5]  M. Gandhi,et al.  Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. , 2018, Blood.

[6]  C. Vetro,et al.  Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy , 2018, Annals of Hematology.

[7]  Y. Oki,et al.  Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma , 2018, British journal of haematology.

[8]  A. Rossi,et al.  Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Miceli,et al.  Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. , 2017, Leukemia research.

[10]  R. Abdah-bortnyak,et al.  Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients , 2017, British journal of haematology.

[11]  A. Sica,et al.  Metabolic regulation of suppressive myeloid cells in cancer. , 2017, Cytokine & growth factor reviews.

[12]  R. Greil,et al.  Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. , 2017, The Lancet. Oncology.

[13]  P. Gobbi,et al.  Neutrophil‐lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients , 2016, Hematological oncology.

[14]  R. Gascoyne,et al.  The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. , 2016, The Lancet. Haematology.

[15]  A. Levis,et al.  Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Pileri,et al.  The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma , 2016, Oncotarget.

[17]  F. d'Amore,et al.  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. , 2016, Blood.

[18]  M. Angelopoulou,et al.  Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. , 2016, The oncologist.

[19]  V. Bumbasirevic,et al.  Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages , 2016, Leukemia & lymphoma.

[20]  R. Advani,et al.  Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era , 2015, British journal of haematology.

[21]  H. Cha,et al.  The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age , 2015, Hematological oncology.

[22]  A. Levis,et al.  The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL) , 2015, American journal of hematology.

[23]  P. Gobbi,et al.  Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. , 2015, Mayo Clinic proceedings.

[24]  C. Vetro,et al.  Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy , 2015, British journal of haematology.

[25]  O. Casasnovas,et al.  The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale , 2014, Haematologica.

[26]  C. Vetro,et al.  Immunological Deregulation in Classic Hodgkin Lymphoma , 2014, Mediterranean journal of hematology and infectious diseases.

[27]  F. Raimondo,et al.  Immunological deregulation in classic hodgkin lymphoma. , 2014 .

[28]  T. Pan,et al.  The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma , 2014, British journal of haematology.

[29]  A. Gallamini,et al.  Standard therapies versus novel therapies in Hodgkin lymphoma. , 2013, Immunology letters.

[30]  A. Gallamini,et al.  Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? , 2012, Blood.

[31]  M. Gandhi,et al.  Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma , 2012, Clinical Cancer Research.

[32]  C. Kim,et al.  Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. , 2012, American journal of clinical pathology.

[33]  T. Habermann,et al.  Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma , 2012, Blood Cancer Journal.

[34]  A. Sica,et al.  Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs) , 2012, Cancer Microenvironment.

[35]  J. Huh,et al.  The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. , 2012, The oncologist.

[36]  C. Vetro,et al.  Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin’s lymphoma , 2012, Haematologica.

[37]  T. Habermann,et al.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma , 2012, Haematologica.

[38]  A. Rossi,et al.  Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses , 2011, British journal of haematology.

[39]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[40]  G. Grabenbauer,et al.  Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma , 2009, Hematological oncology.

[41]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Hasenclever.  The disappearance of prognostic factors in Hodgkin's disease. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[44]  F. Magyari,et al.  Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma , 2015, International Journal of Hematology.